TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This trial is a multi-center, single-arm, open-label, Phase I clinical trial in 3 phases:
dose escalation phase, dose expansion phase and indication expansion phase, which will
explore the safety, tolerability, PK and preliminary efficacy of TGRX-326 in patients with
ALK-positive or ROS1-positive advanced NSCLC.